We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Pilot Comparison of Standard Antiviral Therapy With and Without 12 Weeks of Betaine in Genotype 1 Naive Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00571714
Recruitment Status : Withdrawn (lack of enrollment)
First Posted : December 12, 2007
Last Update Posted : September 19, 2017
Information provided by (Responsible Party):
Mark Mailliard, MD, University of Nebraska

Brief Summary:

The primary purpose of the study is to compare the safety and effectiveness of standard treatment for chronic hepatitis C using peginterferon alpha-2a (Pegasys) and ribavirin (Copegus) to those same medications plus a dietary supplement called betaine when added for the first 12 weeks of treatment.

Peginterferon alpha-2a (Pegasys) and ribavirin (Copegus) are approved by the FDA (Food and Drug Administration) for the treatment of chronic hepatitis C.

Betaine is a dietary supplement and occurs naturally in the body. It is not a medication regulated by the FDA or an approved drug for chronic hepatitis C.

Condition or disease Intervention/treatment
Chronic Hepatitis C Drug: Peginterferon alpha-2a and ribavirin Drug: Peginterferon alpha-2a , ribavirin and betaine

Detailed Description:

Although pegylated alpha interferon and ribavirin will likely be part of the core therapy for chronic HCV for the next several years, there are a number of complimentary antiviral agents in development including protease or polymerase inhibitors, RNA vaccines and immunomodulators (5). However, it would be unlikely to have FDA approval for any of these newer agents before the next 3 - 5 years, i.e. 2010-2012.

Betaine, a naturally occurring anti-oxidant metabolite of choline and an amino acid analog (tri-methyl-glycine), serves as a methylation agent to re-methylate damaged cell proteins or enzymes (6). By virtue of its metabolic role in decreasing toxic metabolites, betaine also protects against alcohol-induced fatty liver and apoptosis. Recently, pilot studies performed both at the Mayo Clinic and here at UNMC showed its applicability as a treatment of non-alcoholic fatty liver in human subjects (7, 8).

Betaine has also recently been found to promote interferon function by overcoming HCV - induced inhibition of interferon signaling (9). Naturally-occurring HCV proteins during human infection can hypo-methylate proteins integral to the Jak - STAT (signal transducers and activators of transcription) pathway, thereby inhibiting the antiviral activity of interferon. In cultured cells betaine administration, in a physiologically attainable concentration, restored STAT methylation and improved interferon signaling (9).

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 0 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Comparison of Standard Therapy,Peginterferon Alpha-2a + Ribavirin for 48 Weeks VS Peginterferon Alph-2a + Ribavirin + Betaine for 12 Weeks Followed by 36 Weeks Standard Therapy in Untreated Adults With Chronic Hepatitis C Genotype 1
Study Start Date : April 2008
Primary Completion Date : March 2010
Study Completion Date : March 2010

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Arm Intervention/treatment
Active Comparator: 1
Peginterferon alpha-2a q week plus weight based ribavirin (800-1400mg/day)in 2 divided daily doses
Drug: Peginterferon alpha-2a and ribavirin
Peginterferon alpha-2a 180mcg by subcutaneous injection every week and weight based ribavirin, 800 to 1400mg/day by mouth in two divided doses every day for 48 weeks
Other Names:
  • Pegasys
  • Copegus
Active Comparator: 2
Peginterferon alpha-2a q week plus weight based ribavirin (800-1400mg/day) in 2 divided daily doses plus betaine (20gm/day) in 2 divided doses for 12 weeks followed by Peginterferon alpha-2a q week plus weight based ribavirin (800-1400mg/day) in 2 divided daily doses for 36 weeks
Drug: Peginterferon alpha-2a , ribavirin and betaine
Peginterferon alpha-2a 180mcg given by subcutaneous injection every week plus weight based ribavirin 800 to 1400 mg/day by mouth in divided doses twice a day plus betaine 10 gm dissolved in juice twice a day for twelve weeks followed by peginterferon alpha-2a 180 mcg given by subcutaneous injection every week plus weight based ribavirin 800 to 1400mg/day by mouth in divided doses twice a day for 36 weeks.
Other Names:
  • Pegasys
  • Copegas

Primary Outcome Measures :
  1. Sustained Viral Response 24 weeks following the end of anti-viral therapy [ Time Frame: 72 weeks ]

Secondary Outcome Measures :
  1. Comparison of rapid and early virologic response in the first 4 and 12 weeks of therapy [ Time Frame: 12 weeks ]
  2. Comparison of the safety of the two treatment regimens [ Time Frame: 48 weeks ]
  3. Comparison of ALT normalization between the two regimens [ Time Frame: 48 weeks ]
  4. Comparison of the effect on interferon gene signaling in peripheral blood mononuclear cells between the two regimens in the first 12 weeks of therapy. [ Time Frame: 12 weeks ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   19 Years to 70 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Subject must be willing to give informed consent and be able to adhere to dose and visit schedules.
  • History of chronic hepatitis C as documented by either anti-HCV or HCV RNA positivity.
  • Adult subjects 19-70 years of age, of either gender
  • Liver biopsy within 3 years prior to the screening 1 visit.
  • Compensated liver disease with the following maximum hematologic, biochemical and serologic criteria at the Screening visit (WNL=within normal limits) Hemoglobin > 12 g/dl for females and >13 g/dl for males, WBC > 3000/mm3, Platelets > 80,000/mm3, Direct Bilirubin - WNL. Indirect bilirubin - WNL, Albumin - WNL, Serum Creatinine - WNL.
  • Fasting glucose should be 70 -140 mg/dl, results between 116-140 require a HbA1c < 8.5%
  • TSH - WNL
  • Subjects with a history of mild depression may be considered for entry in to this study provided that a pretreatment assessment of the subject's affective status supports that the subject is clinically stable.
  • Subjects with a history of substance abuse must have abstained from using the substance for at least one year prior to the Screening visit.
  • Antinuclear antibodies (ANA) < 1:320
  • No radiologic evidence of a focal mass suggestive of hepatoma and/or ascites.

Exclusion Criteria:

  • Pregnant or nursing subjects. Subjects who intend to become pregnant during the study period. Subjects with partners who intend to become pregnant during the study period.
  • History of new hepatitis C exposure within the last 6 months
  • Prior treatment for chronic hepatitis C.
  • Current or intended use of G-CSF and/or GM-CSF during the stud period is prohibited. Current use of erythropoietin (EPO) is prohibited.
  • Suspected hypersensitivity to any interferon product or ribavirin
  • Participation in any other clinical trial within 30 days of Screening visit
  • Treatment with any investigational drug within 30 days of Screening visit 1.
  • Any other cause for liver disease other than CHC.
  • Coagulopathies including hemophilia
  • Hemoglobinopathies
  • G6PD deficiency
  • Coinfection with HIV and/or HBV
  • Evidence of active or suspected malignancy or a history of malignancy within the last five years (with the exception of adequately treated basal cell carcinoma of the skin).
  • Evidence of decompensated liver disease such as history or presence of ascites, bleeding varices or hepatic encephalopathy
  • Subjects with organ transplants other than cornea or hair transplant
  • Any Known preexisting medical condition, that could interfere with the subject's participation in and completion of the study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00571714

United States, Nebraska
Nebraska Medical Center
Omaha, Nebraska, United States, 68198
Sponsors and Collaborators
University of Nebraska
Principal Investigator: Mark E Mailliard, M.D. University of Nebraska

Responsible Party: Mark Mailliard, MD, UNMC Principal Investigator, University of Nebraska
ClinicalTrials.gov Identifier: NCT00571714     History of Changes
Other Study ID Numbers: 159-07-FB
First Posted: December 12, 2007    Key Record Dates
Last Update Posted: September 19, 2017
Last Verified: September 2017

Keywords provided by Mark Mailliard, MD, University of Nebraska:
Chronic hepatitis C
Pilot Comparison
Peginterferon alph-2a
Genotype 1
Treatment naive

Additional relevant MeSH terms:
Hepatitis A
Hepatitis C
Hepatitis, Chronic
Hepatitis C, Chronic
Liver Diseases
Digestive System Diseases
Hepatitis, Viral, Human
Virus Diseases
Enterovirus Infections
Picornaviridae Infections
RNA Virus Infections
Flaviviridae Infections
Peginterferon alfa-2a
Molecular Mechanisms of Pharmacological Action
Antiviral Agents
Anti-Infective Agents
Immunologic Factors
Physiological Effects of Drugs
Gastrointestinal Agents
Lipotropic Agents
Hypolipidemic Agents
Lipid Regulating Agents